APA-viite

Seelig, E., Howlett, J., Porter, L., Truman, L., Heywood, J., Kennet, J., . . . Waldron-Lynch, F. (2018). The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. JCI Insight.

Chicago-tyylinen lähdeviittaus

Seelig, Eleonora, et al. "The DILfrequency Study Is an Adaptive Trial to Identify Optimal IL-2 Dosing in Patients With Type 1 Diabetes." JCI Insight 2018.

MLA-viite

Seelig, Eleonora, et al. "The DILfrequency Study Is an Adaptive Trial to Identify Optimal IL-2 Dosing in Patients With Type 1 Diabetes." JCI Insight 2018.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.